An investigation revealed that the US Army spent around $880,000 on anti-snake venom drugs last year, specifically Polyserp and Polyserp-P, without adequate independent testing for their safety or efficacy. These drugs are not endorsed by the World Health Organization and were not assessed by the US FDA, raising concerns about their effectiveness. This issue coincides with a focus on addressing the neglected crisis of snakebites at the World Health Assembly, highlighting the urgency for effective antivenoms in vulnerable communities worldwide.
Investigations have brought to light that the anti-snake venom drugs purchased by the US army for nearly $1 million last year lack independent testing for safety or effectiveness.
The two anti-snake venom drugs, Polyserp and its regional variant Polyserp-P, reportedly demonstrate questionable efficacy despite significant military investment in their procurement.
Collection
[
|
...
]